Order Article Reprints

Nehring M, Pugh S, Dihle T, Gallichotte E, Nett T, Weber E, Mayo C, Lynn L, Ebel G, Fosdick BK, et al. Laboratory-Based SARS-CoV-2 Receptor Binding Domain Serologic Assays Perform with Equivalent Sensitivity and Specificity to Commercial FDA-EUA Approved Tests. Viruses. 2023; 15(1):106. https://doi.org/10.3390/v15010106

Nehring, Mary, Sierra Pugh, Tina Dihle, Emily Gallichotte, Terry Nett, Eric Weber, Christie Mayo, Lori Lynn, Greg Ebel, Bailey K. Fosdick, and et al. 2023. "Laboratory-Based SARS-CoV-2 Receptor Binding Domain Serologic Assays Perform with Equivalent Sensitivity and Specificity to Commercial FDA-EUA Approved Tests" Viruses 15, no. 1: 106. https://doi.org/10.3390/v15010106

Nehring, M., Pugh, S., Dihle, T., Gallichotte, E., Nett, T., Weber, E., Mayo, C., Lynn, L., Ebel, G., Fosdick, B. K., & VandeWoude, S. (2023). Laboratory-Based SARS-CoV-2 Receptor Binding Domain Serologic Assays Perform with Equivalent Sensitivity and Specificity to Commercial FDA-EUA Approved Tests. Viruses, 15(1), 106. https://doi.org/10.3390/v15010106